OncoGxOne™ Discovery Cancer Panels

GENEWIZ OncoGxOne™ Discovery cancer panels provide comprehensive genomic analysis for cancer research, biomarker discovery, and patient stratification. Designed and developed with the most recent research data available, these assays provide thorough assessments on cancer genes of interest.  For additional information, please refer to our OncoGxOne™ Discovery Cancer Panels FAQ.


Request Quote   

Applications

Cancer mechanism studies, such as identifying novel driving mutations
Cancer therapeutic target discovery
Cancer biomarker discovery
Patient stratification
Personalized cancer treatment

Features & Benefits

19 cancer-type specific panels
Each panel assays a range of 150-400 tumor-specific genes, providing flexibility of adding or subtracting genes of your liking
Panels target full exonic and UTR regions, as well as select intronic regions implicated in breakpoints
Designed and verified to provide thorough coverage of specific cancer loci of interest
Ability to detect all types of genomic aberrations, including SNPs, INDELS, rearrangements, and CNVs
Extremely high depth of coverage to detect common and rare mutations
Very low input DNA requirement
Sequencing compatibility with FFPE samples
Customizability of cancer panels to add additional genes of interest
Complete solution, from project design through custom data analysis
Fast turnaround time with expedited options available

Cancer Types Assayed by GENEWIZ OncoGxOne™ Discovery Panels*

  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Thyroid Cancer

*Development of assays for other cancer types with flexibility to add or subtract genes from premade panels available upon request.



Cancer Panel Comparison


Azenta Pan-Cancer Pane GENEWIZ OncoGxOneTM
Discovery Cancer Panels
Illumina TruSeq©
Amplicon Cancer Panel
Sequencing Platform Illumina MiSeq or HiSeq Illumina MiSeq or HiSeq Illumina MiSeq
Cancer Types Assayed Single gene panel assay for multiple cancer types
19 distinct gene panels, each assays a specific cancer (organ) type Single gene panel assays multiple cancer types
Genes Covered 634 ≈150 - 400 48
Genomic Variation Detection
  • Point Mutations
  • Indels
  • Copy Number Variations (CNV)
    • Point Mutations
    • Indels
    • Rearrangements
    • Copy Number Variations (CNV)
    • Point Mutations
    • Indels
    Target Regions ≈ 2 Mb, consisting of exons and targeted promoter regions ≈ 2 - 5.4 Mb, consisting of all exons, UTRs, and relevant intron regions ≈35 Kb, consisting of mutational hot spots
    Average Depth >100x* > 100x* > 100x*
    Target Enrichment Twist Targeted Enrichment Agilent SureSelect Targeted Enrichment Illumina Targeted Amplicon Sequencing
    DNA Input > 100 ng > 100 ng > 250 ng
    Sample Submission
    • FFPE thin sections (slides)
    • gDNA
    • Fresh, frozen samples
    • FFPE thin sections (slides)
    • gDNA
    • Fresh, frozen samples
    • FFPE thin sections (slides)
    • gDNA
    *Additional depth of coverage is available by request.

    Sample Submission Guidelines

    GENEWIZ accepts formalin-fixed, paraffin-embedded (FFPE) thin sections (slides), purified genomic DNA, or fresh, frozen samples for Cancer Panel projects. For detailed sample submission requirements please visit our Sample Submission Guidelines page.


    Deliverables

    All customers receive their raw data as FASTQ files. Mutation discovery and customizable data analysis packages are available by request.


    Technical Resources

    Webinar| Non-Classical Sources of Tumour-Specific Antigen in Checkpoint Inhibitor Response

    Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.

    Certified Illumina Sequencing Provider

    Azenta is a certified service provider for Illumina and Life Technology NGS platforms. For information on our NGS platforms as well as recommended configurations for your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing only projects.



    How To Order


    Email | Phone +49 (0)341 520 122-41